Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This was a feasibility study aimed at elevating protease inhibitors (PI) dosage as a part of
active antiretroviral therapy (HAART). After the pharmacokinetics for the currently
prescribed PI were determined,patients with a vIQ<1 were eligible for a 50% dose increase for
an 8 week time frame after which their vIQ would be reassessed to determine if increasing
their PI dosage thereby increasing the bioavaiability would reduce their viral load.
Details
Lead Sponsor:
Children's National Research Institute Children's Research Institute